PCR-based genotyping for duplicated and deleted CYP2D6 genes

Area of Science:

• Pharmacogenomics
• Molecular biology
• Drug metabolism

Background:

• The CYP2D6 enzyme is crucial for metabolizing over 30 common drugs.
• Polymorphisms in CYP2D6 can lead to adverse drug reactions or treatment failure due to altered enzyme activity.
• Understanding CYP2D6 genetic variations is essential for optimizing drug therapy.

Purpose of the Study:

• To develop and describe PCR-based methods for detecting CYP2D6 gene copy number variations (duplications or deletions).
• To enable accurate genotyping of individuals across the spectrum of CYP2D6 metabolic activity.
• To provide a tool for the individualization of drug therapy based on CYP2D6 genotype.

Main Methods:

• Polymerase Chain Reaction (PCR) amplification of the entire CYP2D6 coding region for control.
• Development of specific PCR-based assays to detect duplicated, multiduplicated, or deleted CYP2D6 active genes.
• Combined analysis of gene copy number and common mutations for comprehensive genotyping.

Main Results:

• Successful development of PCR methods for detecting CYP2D6 gene duplications and deletions.
• The methods allow for the amplification of the entire coding region as a control.
• Enables differentiation of individuals into poor, intermediate, rapid, and ultrarapid metabolizer phenotypes.

Conclusions:

• The described PCR-based genotyping methods are efficient for analyzing CYP2D6 gene copy number variations.
• These methods facilitate the accurate classification of individuals based on their CYP2D6 metabolic capacity.
• This provides a valuable tool for personalizing drug selection and dosage, improving therapeutic outcomes and reducing side effects.